Myeloid-Adaptive Response to Atezolizumab (MARTA): A Two-Gene CXCL13–CXCL8 Transcriptomic Biomarker Across…

Abstract

Transcriptomic response biomarkers for immune-checkpoint blockade remain poorly defined across cancers. We developed the two-gene Myeloid-Adaptive Response to Atezolizumab (MARTA) score, integrating CXCL13 and CXCL8 expression. MARTA was developed in 81 atezolizumab-treated patients in IMmotion150, evaluated across treatment groups, and independently assessed in IMvigor210. In IMmotion150, higher MARTA was associated with higher objective response rate (ORR) with atezolizumab alone (odds ratio [OR], 3.20; 95% confidence interval [CI], 1.42–7.19) and atezolizumab plus bevacizumab (OR, 2.61; 95% CI, 1.43–4.76), but not with sunitinib. Higher MARTA was associated with longer progression-free survival (PFS) in both atezolizumab-containing groups (hazard ratio [HR], 0.60 and 0.65), but not with sunitinib (interaction p = 0.01). In IMvigor210, higher MARTA was associated with higher ORR (OR per 1-standard-deviation increase, 1.38; 95% CI, 1.05–1.81) and longer overall survival (OS) (HR, 0.76; 95% CI, 0.67–0.86). The OS association remained after multivariate adjustment (HR, 0.81; 95% CI, 0.69–0.95). Discrimination for ORR and OS, assessed by the area under the curve (AUC) and C-index, respectively, was modest for MARTA, tGE8, and the IFN-γ signature. These findings support further evaluation of MARTA, while prospective validation and cross-platform analytical reproducibility remain necessary before clinical application.

Multiplexed FRET-FLIM Profiling of Immune Checkpoint Interactions Predicts Response to Atezolizumab in Urothelial Carcinoma
L. Camacho, C. Cacho-Navas, J. Agüero +11
medRxiv1 Sep 2026PreprintAll rights reservedFull textOncologymedRxiv
A 5-gene mutation signature predicts response to atezolizumab in metastatic bladder urothelial carcinoma.
Dongmei Han, Caihong Wu, Dan Wang +2
Translational andrology and urology28 Sep 2026Peer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
Integrated Transcriptomic and Network Analysis Identifies Diagnostic and Immune-Associated Hub Genes in Urothelial Carcinoma
Shaza N. Alkhatib, Ammena Y. Binsaleh, Nawal Al-Hoshani +3
Biomedicines1 Oct 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC
Advances in Novel Protein Acylation in Urothelial Carcinoma: Research Progress and Biomarker Potential
Xiyue Dong, Jiankun Zhang, Meixi Liu +2
Oncology Research28 Oct 2026Peer-reviewedCC BY 4.0Full textSurgery & anaesthesiaPMC
Incremental Predictive Value and Representation of Transcriptomic Features for Immunotherapy Response in Advanced Urothelial Carcinoma
G. Y. Han, H. Tai, F. Wang
medRxiv14 Sep 2026PreprintCC BYFull textOncologymedRxiv

Cite

BibTeX RIS

BibTeX

@article{uccello2026myeloidadaptive,
  title = {{Myeloid-Adaptive Response to Atezolizumab (MARTA): A Two-Gene CXCL13–CXCL8 Transcriptomic Biomarker Across Renal Cell and Urothelial Carcinoma}},
  author = {Mario Uccello},
  journal = {Current issues in molecular biology},
  year = {2026},
  month = oct,
  doi = {10.3390/cimb48101012},
  url = {https://europepmc.org/article/PMC/PMC13703666},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - Myeloid-Adaptive Response to Atezolizumab (MARTA): A Two-Gene CXCL13–CXCL8 Transcriptomic Biomarker Across Renal Cell and Urothelial Carcinoma
AU  - Mario Uccello
PY  - 2026
DA  - 2026/10/01
JO  - Current issues in molecular biology
DO  - 10.3390/cimb48101012
UR  - https://europepmc.org/article/PMC/PMC13703666
AB  - Transcriptomic response biomarkers for immune-checkpoint blockade remain poorly defined across cancers. We developed the two-gene Myeloid-Adaptive Response to Atezolizumab (MARTA) score, integrating CXCL13 and CXCL8 expression. MARTA was developed in 81 atezolizumab-treated patients in IMmotion150, evaluated across treatment groups, and independently assessed in IMvigor210. In IMmotion150, higher MARTA was associated with higher objective response rate (ORR) with atezolizumab alone (odds ratio [OR], 3.20; 95% confidence interval [CI], 1.42–7.19) and atezolizumab plus bevacizumab (OR, 2.61; 95% CI, 1.43–4.76), but not with sunitinib. Higher MARTA was associated with longer progression-free survival (PFS) in both atezolizumab-containing groups (hazard ratio [HR], 0.60 and 0.65), but not with sunitinib (interaction p = 0.01). In IMvigor210, higher MARTA was associated with higher ORR (OR per 1-standard-deviation increase, 1.38; 95% CI, 1.05–1.81) and longer overall survival (OS) (HR, 0.76; 95% CI, 0.67–0.86). The OS association remained after multivariate adjustment (HR, 0.81; 95% CI, 0.69–0.95). Discrimination for ORR and OS, assessed by the area under the curve (AUC) and C-index, respectively, was modest for MARTA, tGE8, and the IFN-γ signature. These findings support further evaluation of MARTA, while prospective validation and cross-platform analytical reproducibility remain necessary before clinical application.
SN  - 1467-3037
SN  - 1467-3045
ER  -

Abstract

Related

Cite